NRG: Name Review Group
The Name Review Group (NRG) is the EMA group that checks whether the proposed name of a centrally authorised medicine could cause confusion or harm.
Also known as: (Invented) Name Review Group, EMA NRG, invented name review
4 min readUpdated
Reviewed by Gosia Luksza, CEO at Regunaut
At a glance
- Part of
- EMA; its conclusions are adopted by the CHMP
- Members
- Member State representatives, chaired by EMA
- Guideline
- EMA/CHMP/287710/2014 Rev. 7, in effect since 1 January 2024
- Request window
- From 18 months before the planned MAA; accepted names valid three years
How it works
The Name Review Group is the body through which EMA applies the naming rules to products in the centralised procedure. Article 6 of Regulation (EC) No 726/2004 requires a single name for a centrally authorised medicine, and Article 1(20) of Directive 2001/83/EC requires an invented name not to be liable to confusion with the common name. The group is made up of representatives of the Member States and chaired by a representative of EMA; the European Commission takes part, and the WHO, patient and healthcare professional organisations and medication safety experts are consulted case by case. Its conclusions go to the CHMP for adoption. The criteria and the procedure are set out in the guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014 Rev. 7), in effect since 1 January 2024.
A request is made on EMA's proposed invented name request form, with the draft SmPC or a product profile. EMA first runs a similarity analysis against the public Article 57 product data and the NRG's own database, which includes names proposed for products that are not yet authorised. The names and the analysis then go to contact points in the national authorities, which check their own registers and the sound and meaning of the name in their languages, and send objections within 30 days. The group discusses each objection at a plenary meeting, using a checklist that weighs the degree of similarity against the potential for harm in a mix-up. After CHMP adoption the applicant receives the outcome with the reasons for, and the source of, each objection.
An applicant can propose at most two names per request for each meeting, with an order of preference, and at most two names can be accepted per application. A name that conflicts only with the name of a pending application is accepted conditionally: both applicants may proceed, but only the product authorised first keeps the name, and the applicants can ask for a bilateral negotiation. A name written as INN plus company name or trade mark is not a default fallback; it needs NRG review as well. After a rejection the applicant can propose new names or submit a justification that answers every objection, which is sent back to the Member States and discussed at the next meeting. EMA's published calendar caps the review at 85 new names per meeting for 2026 and 2027, first come, first served, so a late request can be deferred.
What goes wrong
Requests are filed with names that were never checked against nationally authorised products, so they attract many objections and the group stops reviewing once rejection is certain; both accepted slots are used on names the company later dislikes, and accepted names cannot be withdrawn simply to make room for better ones; the validity period lapses before the application is submitted because nobody tracked it; the product profile changes after acceptance and the NRG is not told; and the request is left so late that no accepted name exists one month before the CHMP opinion, in which case the opinion is adopted under the common name with the name of the holder. The NRG covers centralised applications only. Names in national, mutual recognition and decentralised procedures are assessed by each Member State, and an NRG acceptance is not a clearance for those procedures. The guide to invented names for medicines covers both routes.
Timing
From 18 months before the MAA
Name review request to EMA, after eligibility is confirmed.
30 days
National authorities check their registers and languages and send objections.
NRG meeting
Objections are discussed, the CHMP adopts the outcome and the applicant is informed.
3 years, plus 1
Validity of an accepted name, with one reconfirmation for a further year.
1 month before the CHMP opinion
The applicant tells EMA which accepted name it will use.
A request can be submitted no earlier than 18 months before the planned submission of the marketing authorisation application, once the CHMP has confirmed that the product is eligible for the centralised procedure. EMA publishes the submission deadlines, NRG meeting dates and CHMP adoption dates for each year. National authorities have 30 days to send objections. An accepted name is valid for three years from CHMP adoption and can be reconfirmed once, for one more year, if the request is made before it expires; once the application is validated the name is in use and does not expire during the procedure. The applicant confirms its chosen name at the latest one month before the CHMP opinion.
What teams do with it in Regunaut
One job in the platform that turn on NRG, each part of a wider workflow.
NRG: common questions
When should a name be submitted to the NRG?
After the CHMP has confirmed that the product is eligible for the centralised procedure, and no earlier than 18 months before the planned submission of the application. Submitting early leaves time for a second round if names are rejected, since the accepted name must be chosen at the latest one month before the CHMP opinion.
How many names can be proposed to the NRG?
Up to two names per request for each meeting, with an order of preference, and up to two names can be accepted for one application. Once two are accepted, further names are reviewed only on justified grounds, such as a safety concern, a conditional acceptance, trade mark problems or difficulty achieving a global name.
How long is an NRG-accepted name valid?
Three years from adoption by the CHMP. The applicant can ask once for reconfirmation, which extends the expiry date by one year if the product profile is unchanged and the request is made before expiry. After a validated application is submitted, the name is treated as in use and does not expire during the procedure.
Does the NRG review names for national or decentralised procedures?
No. The NRG reviews names for products in the centralised procedure. In national, mutual recognition and decentralised procedures each Member State assesses the name under its own guidance. The NRG does take nationally authorised names into account when it looks for conflicts with a proposed name.
Guides that cover NRG
Sources
- European Medicines Agency: Guideline on the acceptability of names for human medicinal products processed through the centralised procedure (EMA/CHMP/287710/2014 Rev. 7)
- European Medicines Agency: (Invented) Name Review Group
- EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products